title: Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer.
abstract: BACKGROUND
  We examined host genetic factors to identify those more common in individuals whose human papillomavirus (HPV) infections were most likely to persist and progress to cervical intraepithelial neoplasia grade 3 (CIN3) and cancer.
  
  
  METHODS
  We genotyped 92 single-nucleotide polymorphisms (SNPs) from 49 candidate immune response and DNA repair genes obtained from 469 women with CIN3 or cancer, 390 women with persistent HPV infections (median duration, 25 months), and 452 random control subjects from the 10,049-woman Guanacaste Costa Rica Natural History Study. We calculated odds ratios and 95% confidence intervals (CIs) for the association of SNP and haplotypes in women with CIN3 or cancer and HPV persistence, compared with random control subjects.
  
  
  RESULTS
  A SNP in the Fanconi anemia complementation group A gene (FANCA) (G501S) was associated with increased risk of CIN3 or cancer. The AG and GG genotypes had a 1.3-fold (95% CI, 0.95-1.8-fold) and 1.7-fold (95% CI, 1.1-2.6-fold) increased risk for CIN3 or cancer, respectively (P(trend) = .008; referent, AA). The FANCA haplotype that included G501S also conferred increased risk of CIN3 or cancer, as did a different haplotype that included 2 other FANCA SNPs (G809A and T266A). A SNP in the innate immune gene IRF3 (S427T) was associated with increased risk for HPV persistence (P(trend) = .009).
  
  
  CONCLUSIONS
  Our results require replication but support the role of FANCA variants in cervical cancer susceptibility and of IRF3 in HPV persistence.
authors.affiliation: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Rm. 5104, Rockville, MD 20852-7234, USA. wangso@mail.nih.gov
authors.forename: Sophia S
authors.initials: SS
authors.lastname: Wang
authors.forename: M Concepcion
authors.initials: MC
authors.lastname: Bratti
authors.forename: Ana Cecilia
authors.initials: AC
authors.lastname: Rodríguez
authors.forename: Rolando
authors.initials: R
authors.lastname: Herrero
authors.forename: Robert D
authors.initials: RD
authors.lastname: Burk
authors.forename: Carolina
authors.initials: C
authors.lastname: Porras
authors.forename: Paula
authors.initials: P
authors.lastname: González
authors.forename: Mark E
authors.initials: ME
authors.lastname: Sherman
authors.forename: Sholom
authors.initials: S
authors.lastname: Wacholder
authors.forename: Z Elizabeth
authors.initials: ZE
authors.lastname: Lan
authors.forename: Mark
authors.initials: M
authors.lastname: Schiffman
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Chanock
authors.forename: Allan
authors.initials: A
authors.lastname: Hildesheim
mesh_terms: D015331:Cohort Studies; D003364:Costa Rica / Q000453:epidemiology; D015344:DNA Probes, HPV; D004260:DNA Repair / Q000235:genetics*; D004279:DNA, Viral / Q000302:isolation & purification; D004268:DNA-Binding Proteins / Q000235:genetics; D018450:Disease Progression; D005090:Exodeoxyribonucleases / Q000235:genetics; D052217:Fanconi Anemia Complementation Group A Protein / Q000235:genetics; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D019255:NADPH Oxidases / Q000235:genetics; D027383:Papillomaviridae / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology; D020641:Polymorphism, Single Nucleotide; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D015344:DNA Probes, HPV; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D052217:Fanconi Anemia Complementation Group A Protein; D000076105:X-ray Repair Cross Complementing Protein 1; D019255:NADPH Oxidases; C086986:CYBA protein, human; D005090:Exodeoxyribonucleases; C028450:exodeoxyribonuclease I